Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ABIO

ARCA biopharma Inc

Apr 18 • 04:00PM ET

3.25

Dollar change +0.04
Percentage change 1.25	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DFAT DFSU

Index	-	P/E	-	EPS (ttm)	-0.37	Insider Own	1.29%	Shs Outstand	14.50M	Perf Week	0.00%
Market Cap	47.12M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	14.31M	Perf Month	86.78%
Income	-5.34M	PEG	-	EPS next Q	-	Inst Own	81.53%	Short Float	1.37%	Perf Quarter	101.86%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	11.34%	Short Ratio	0.14	Perf Half Y	59.31%
Book/sh	2.55	P/B	1.27	EPS next Y	-	ROA	-13.19%	Short Interest	0.20M	Perf Year	62.50%
Cash/sh	2.58	P/C	1.26	EPS next 5Y	-	ROE	-13.57%	52W Range	1.56 - 3.88	Perf YTD	91.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	48.59%	ROI	-14.34%	52W High	-16.24%	Beta	0.92
Dividend TTM	-	Quick Ratio	59.01	Sales past 5Y	0.00%	Gross Margin	-	52W Low	108.33%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	59.01	EPS Y/Y TTM	46.28%	Oper. Margin	0.00%	RSI (14)	77.31	Volatility	5.35% 6.34%
Employees	5	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	17.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	7.85%	Payout	-	Rel Volume	0.16	Prev Close	3.21
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Oct 18 AMC	Avg Volume	1.40M	Price	3.25
SMA20	28.61%	SMA50	62.11%	SMA200	68.47%	Trades		Volume	218,431	Change	1.25%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-27-18	Initiated	Ascendiant Capital Markets	Buy	$2
Oct-09-13	Initiated	Dawson James	Buy	$3.75

Apr-03-24 02:30PM	Why Is ARCA Biopharma (ABIO) Stock Up 85% Today? (InvestorPlace) +90.06%
12:00PM	Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details (Benzinga)
07:30AM	ARCA biopharma and Oruka Therapeutics Announce Merger Agreement (GlobeNewswire)
Feb-01-24 04:35PM	ARCA biopharma Announces 2023 Financial Results (GlobeNewswire)
Oct-18-23 04:25PM	ARCA biopharma Announces Third Quarter 2023 Financial Results (GlobeNewswire)
04:25PM	Loading…
Jul-21-23 04:25PM	ARCA biopharma Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-13-23 11:30AM	We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Apr-24-23 04:25PM	ARCA biopharma Announces First Quarter 2023 Financial Results (GlobeNewswire)
Feb-24-23 04:20PM	ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-03-23 10:19AM	Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation (Simply Wall St.)
Dec-19-22 04:05PM	James Flynn Joins ARCA biopharma Board of Directors (GlobeNewswire)
Nov-14-22 09:24AM	One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year (Simply Wall St.)
Oct-28-22 04:15PM	ARCA biopharma Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 04:15PM	ARCA biopharma Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-18-22 06:14AM	Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
04:05PM	Loading…
Jun-21-22 04:05PM	Jacob Ma-Weaver Joins ARCA biopharma Board of Directors (GlobeNewswire)
May-05-22 04:15PM	ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review (GlobeNewswire) -5.79%
May-02-22 04:15PM	ARCA biopharma Announces First Quarter 2022 Financial Results (GlobeNewswire)
Apr-18-22 04:30PM	ARCA biopharma Establishes Special Committee of the Board of Directors (GlobeNewswire)
Apr-05-22 01:35AM	Albioma : Governance changes (GlobeNewswire)
Apr-01-22 07:09AM	ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study (Benzinga)
Mar-31-22 04:15PM	ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial (GlobeNewswire)
Mar-14-22 04:15PM	ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-22 04:30PM	Battalion Oil Corporation Announces Fourth Quarter and Full Year 2021 Financial and Operating Results (GlobeNewswire)
Feb-08-22 04:21AM	We're Keeping An Eye On ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Jan-04-22 08:30AM	Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2 (GlobeNewswire)
Dec-02-21 08:30AM	ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19 (GlobeNewswire)
Nov-20-21 07:01AM	ClearPoint Neuro (NASDAQ:CLPT) shareholders are still up 635% over 3 years despite pulling back 13% in the past week (Simply Wall St.)
Nov-09-21 04:15PM	ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th (GlobeNewswire)
Nov-02-21 04:15PM	ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
07:03AM	Loading…
Oct-29-21 07:03AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:26AM	ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged (Benzinga)
Oct-28-21 04:30PM	ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data (GlobeNewswire)
Sep-16-21 08:30AM	ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire)
Aug-16-21 08:05AM	ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th (GlobeNewswire) -5.14%
Aug-12-21 01:15AM	We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-09-21 08:00AM	ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2 (GlobeNewswire)
Aug-04-21 04:15PM	ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-28-21 08:00AM	Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology (GlobeNewswire)
Jul-13-21 08:00AM	ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire) -14.09%
Jul-09-21 08:00AM	ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th (GlobeNewswire) +5.75%
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE) -6.95%
Jul-07-21 08:00AM	ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement (GlobeNewswire) +9.36%
Jun-23-21 09:35AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE)
May-11-21 04:15PM	ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-21 04:05PM	Christopher Graybill Joins ARCA as Vice President, Clinical Development (GlobeNewswire)
May-03-21 04:30PM	ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer (GlobeNewswire)
Mar-18-21 04:30PM	ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-13-21 01:09AM	Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation (Simply Wall St.)
Dec-15-20 08:30AM	ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 (GlobeNewswire)
Dec-09-20 05:40PM	ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders (GlobeNewswire)
Nov-23-20 12:28PM	ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment (MarketWatch) +7.46%
08:30AM	AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation (GlobeNewswire)
Nov-02-20 08:30AM	ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire) +5.19%
Oct-07-20 08:30AM	ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19 (GlobeNewswire) -8.49%
Oct-05-20 04:30PM	ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality (GlobeNewswire)
Sep-21-20 08:00AM	ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19 (GlobeNewswire) -10.62%
Aug-17-20 08:49AM	We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-12-20 08:00AM	ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19 (ACCESSWIRE) -7.51%
Aug-05-20 04:15PM	Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-07-20 08:30AM	SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators (GlobeNewswire)
Jun-03-20 09:56AM	ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering (GlobeNewswire) -5.39%
09:56AM	Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More (Zacks)
Jun-01-20 08:20AM	ARCA Biopharma Announces $9.4 Million Registered Direct Offering (GlobeNewswire) -26.98%
May-29-20 12:24PM	A Mighty May: Over $200,000 In Gross Profits (Benzinga) -34.41%
09:59AM	Company News for May 29, 2020 (Zacks)
May-28-20 04:19PM	Arca Biopharma Nearly Quintuples On Plans To Test A Coronavirus Drug (Investor's Business Daily) +386.33%
12:14PM	Arca Biopharma Stock Triples On Plans To Test A Coronavirus Treatment (Investor's Business Daily)
10:27AM	Price Over Earnings Overview: ARCA biopharma (Benzinga)
08:00AM	ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy (GlobeNewswire)
May-07-20 08:30AM	Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions (GlobeNewswire)
May-06-20 04:30PM	ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update (GlobeNewswire)
Feb-18-20 04:30PM	ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-01-20 08:31AM	Does Market Volatility Impact ARCA biopharma, Inc.'s (NASDAQ:ABIO) Share Price? (Simply Wall St.)
Nov-06-19 04:10PM	ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-19 08:47AM	Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Invest In Growth? (Simply Wall St.)
Sep-12-19 08:30AM	ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium (GlobeNewswire)
Sep-11-19 08:30AM	Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting (GlobeNewswire) +13.16%
Sep-04-19 01:37PM	Could The ARCA biopharma, Inc. (NASDAQ:ABIO) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Aug-21-19 09:49AM	INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (GlobeNewswire) +8.08%
Aug-01-19 04:30PM	ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update (GlobeNewswire) -7.30%
Jun-04-19 07:09AM	One Thing To Remember About The ARCA biopharma, Inc. (NASDAQ:ABIO) Share Price (Simply Wall St.)
May-13-19 09:00AM	ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure (GlobeNewswire) -10.00%
May-08-19 04:30PM	ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update (GlobeNewswire) +20.03%
May-01-19 08:30AM	GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure (GlobeNewswire) +98.64%
Apr-23-19 08:30AM	ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial (GlobeNewswire)
Mar-18-19 08:30AM	Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology (GlobeNewswire)
Mar-06-19 08:00AM	Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine (GlobeNewswire)
Feb-27-19 04:15PM	ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-20-19 07:30AM	ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug (GlobeNewswire) +31.27%
Jan-16-19 08:30AM	Zosano Appoints Linda Grais M.D., J.D. to Board of Directors (GlobeNewswire)
Dec-26-18 11:47AM	ARCA biopharma, Inc. (NASDAQ:ABIO) Insiders Have Been Selling (Simply Wall St.) -7.06%
Dec-20-18 04:01PM	ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial (GlobeNewswire) -25.26%
Nov-14-18 04:30PM	ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update (GlobeNewswire) -6.94%
Nov-12-18 08:30AM	GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions (GlobeNewswire)
Nov-05-18 08:30AM	ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions (GlobeNewswire) +13.17%
Oct-10-18 04:16PM	Westminster biotech company receives second extension on delisting notice from Nasdaq (American City Business Journals) -5.43%
Oct-02-18 08:00AM	Today's Research Reports on Trending Tickers: ARCA biopharma and Nektar Therapeutics (ACCESSWIRE) -35.29%
Sep-18-18 08:30AM	ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial (GlobeNewswire)
Aug-09-18 04:15PM	ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update (GlobeNewswire)

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Open in Screener

ALPN

Alpine Immune Sciences Inc

Apr 18 • 04:00PM ET

64.43

Dollar change -0.03
Percentage change -0.05	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ALPN Alpine Immune Sciences Inc daily Stock Chart

Held by: VTI IWM VXF IBB SCHA LABU IWO IWN DWAS PTH

Index	RUT	P/E	-	EPS (ttm)	-0.69	Insider Own	28.22%	Shs Outstand	60.35M	Perf Week	0.05%
Market Cap	4.22B	Forward P/E	-	EPS next Y	-1.96	Insider Trans	-16.24%	Shs Float	47.05M	Perf Month	61.28%
Income	-32.18M	PEG	-	EPS next Q	-0.43	Inst Own	68.40%	Short Float	11.23%	Perf Quarter	232.97%
Sales	58.88M	P/S	71.73	EPS this Y	-174.80%	Inst Trans	37.61%	Short Ratio	2.51	Perf Half Y	531.67%
Book/sh	5.43	P/B	11.86	EPS next Y	-11.44%	ROA	-9.63%	Short Interest	5.28M	Perf Year	762.52%
Cash/sh	4.99	P/C	12.90	EPS next 5Y	-	ROE	-12.69%	52W Range	6.71 - 64.57	Perf YTD	238.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.56%	ROI	-9.55%	52W High	-0.22%	Beta	0.96
Dividend TTM	-	Quick Ratio	7.86	Sales past 5Y	171.70%	Gross Margin	99.02%	52W Low	860.21%	ATR (14)	2.93
Dividend Ex-Date	-	Current Ratio	7.86	EPS Y/Y TTM	58.73%	Oper. Margin	-75.16%	RSI (14)	83.41	Volatility	0.19% 6.43%
Employees	142	Debt/Eq	0.03	Sales Y/Y TTM	95.84%	Profit Margin	-54.66%	Recom	2.75	Target Price	65.00
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	124.03%	Payout	-	Rel Volume	1.17	Prev Close	64.46
Sales Surprise	238.91%	EPS Surprise	145.45%	Sales Q/Q	1011.42%	Earnings	Mar 18 AMC	Avg Volume	2.11M	Price	64.43
SMA20	41.78%	SMA50	68.14%	SMA200	215.45%	Trades		Volume	2,461,199	Change	-0.05%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-24	Initiated	Guggenheim	Buy	$55
Feb-15-24	Initiated	Wolfe Research	Outperform	$44
Oct-18-23	Initiated	Berenberg	Buy	$18
Oct-17-23	Initiated	Berenberg	Buy	$18
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$19
Jun-26-23	Resumed	Oppenheimer	Outperform	$14
Jan-19-23	Initiated	Morgan Stanley	Overweight	$17
Nov-21-22	Initiated	SVB Leerink	Outperform	$15
Dec-21-20	Initiated	H.C. Wainwright	Buy	$21
Aug-26-20	Initiated	Cowen	Outperform

Today 08:30AM	Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy? (Motley Fool)
Apr-15-24 09:15AM	Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock (Motley Fool)
Apr-13-24 05:29AM	Could This Stock Be the Next Biotech Buyout? (Motley Fool)
Apr-12-24 12:36PM	Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex (Zacks)
10:55AM	Health Care Roundup: Market Talk (The Wall Street Journal)
04:43PM	Loading…
Apr-11-24 04:43PM	These Stocks Moved the Most Today: CarMax, Apple, Fastenal, Rivian, Alpine Immune, Nike, Robinhood, Constellation Brands, and More (Barrons.com) +36.90%
04:29PM	Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal (Yahoo Finance Video)
04:18PM	Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It (Investor's Business Daily)
01:59PM	Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands (The Wall Street Journal)
01:07PM	These Stocks Are Moving the Most Today: CarMax, Fastenal, Rivian, Alpine Immune, Nike, Robinhood, Constellation Brands, and More (Barrons.com)
11:58AM	Top Stock Movers Now: Nike, Constellation Brands, Fastenal, and More (Investopedia)
11:03AM	Vertex Pharmaceuticals Seeks a Second Act With Alpine Immune Deal. What Wall Street Says. (Barrons.com)
09:47AM	These Stocks Are Moving the Most Today (Barrons.com)
09:47AM	The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today (InvestorPlace)
09:39AM	Vertex to Pay $4.9 Billion for Kidney Disease Drug Developer (Bloomberg)
07:34AM	Loading…
07:34AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Apr-10-24 10:34PM	Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B Key Level to Watch (Investopedia) +20.80%
07:05PM	Biotech giant Vertex bought Alpine in a cash deal of $4.9 billion (Quartz)
05:47PM	Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion (The Wall Street Journal)
05:14PM	Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal (Investor's Business Daily)
04:19PM	Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal (Reuters)
04:16PM	UPDATE 3-Vertex Pharma bets on kidney disease treatment with $4.9 bln Alpine Immune deal (Reuters)
04:15PM	Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy (Business Wire)
04:06PM	Vertex to acquire Alpine Immune Sciences for $4.9 bln (Reuters)
04:01PM	Vertex Enters Into Agreement to Acquire Alpine Immune Sciences (Business Wire)
01:34PM	Vertex to buy kidney disease drugmaker Alpine for $4.9B (BioPharma Dive)
Apr-09-24 09:23AM	Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last? (Zacks)
Apr-01-24 09:00AM	Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024 (Business Wire)
Mar-21-24 07:45AM	Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024 (Business Wire)
Mar-20-24 04:30PM	Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (Business Wire)
08:32AM	Loading…
Mar-19-24 08:32AM	Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.63%
06:48AM	Q4 2023 Alpine Immune Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-18-24 08:53PM	ALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:25PM	Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates (Zacks)
05:31PM	Alpine Immune Sciences Inc (ALPN) Reports Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results (Business Wire)
Mar-14-24 08:38AM	Is a Surprise Coming for Alpine Immune Sciences (ALPN) This Earnings Season? (Zacks)
Mar-11-24 10:00AM	Alpine Immune Sciences, Inc. (ALPN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Mar-07-24 04:30PM	Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-26-24 04:30PM	Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences (Business Wire)
Feb-01-24 04:30PM	Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences (Business Wire) +5.15%
Dec-21-23 04:15PM	Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie (Business Wire)
Dec-19-23 09:50AM	Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year? (Zacks) +5.39%
Dec-18-23 04:30PM	Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-06-23 09:55AM	Wall Street Analysts See a 56.25% Upside in Alpine Immune Sciences, Inc. (ALPN): Can the Stock Really Move This High? (Zacks) +5.73%
Nov-29-23 09:40AM	Is Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-20-23 04:30PM	Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference (Business Wire)
09:55AM	Wall Street Analysts Think Alpine Immune Sciences, Inc. (ALPN) Could Surge 79.37%: Read This Before Placing a Bet (Zacks)
Nov-17-23 07:44PM	Six Flags, Howard Hughes, and More Stocks See Action From Activist Investors (Barrons.com) +5.69%
Nov-15-23 09:00AM	Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023 (Business Wire) +5.60%
Nov-14-23 08:55PM	Alpine Immune Sciences Inc (ALPN) Reports Encouraging Q3 2023 Results; Advances Povetacicept ... (GuruFocus.com)
04:15PM	Alpine Immune Sciences Reports Third Quarter 2023 Financial Results (Business Wire)
03:57PM	Orbimed Advisors LLC Bolsters Portfolio with Alpine Immune Sciences Inc Stake (GuruFocus.com)
Nov-13-23 09:00AM	Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023 (Business Wire) -5.40%
Nov-06-23 09:41PM	Alpine Immune Sciences Announces Pricing of $150 Million Public Offering (Business Wire) -12.07%
06:00AM	Alpine Immune Sciences Announces Proposed Public Offering (Business Wire)
Nov-03-23 09:00AM	Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting (Business Wire) +9.17%
Nov-02-23 09:00AM	Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023 (Business Wire) +39.92%
Oct-30-23 10:01AM	Alpine Immune Sciences, Inc. (ALPN) Surges 8.9%: Is This an Indication of Further Gains? (Zacks) +5.16%
09:00AM	Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023 (Business Wire)
Oct-27-23 09:40AM	Are Medical Stocks Lagging Alcon (ALC) This Year? (Zacks) +8.90%
Oct-23-23 12:00PM	Alpine Immune Sciences, Inc. (ALPN) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) -8.87%
Oct-13-23 09:05AM	Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023 (Business Wire) -6.13%
Oct-12-23 12:13PM	Lilly (LLY) Up on NVO's Ozempic Early Success in Kidney Study (Zacks)
Oct-11-23 10:15AM	Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit (Zacks)
Oct-09-23 11:10AM	J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC (Zacks)
Oct-06-23 09:55AM	Wall Street Analysts Believe Alpine Immune Sciences, Inc. (ALPN) Could Rally 50.37%: Here's is How to Trade (Zacks)
09:24AM	AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker (Zacks)
Oct-04-23 08:17AM	AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M (Zacks)
08:00AM	Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c) (Business Wire)
Oct-03-23 07:43AM	Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection (Zacks)
Sep-18-23 08:52AM	5 Stocks to Buy as Drug Industry Displays Strong Fundamentals (Zacks)
Sep-12-23 08:30AM	Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting (Business Wire)
Sep-08-23 09:40AM	Has SiBone (SIBN) Outpaced Other Medical Stocks This Year? (Zacks)
Sep-05-23 04:30PM	Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences (Business Wire)
08:30AM	Alpine Immune Sciences to Present First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting (Business Wire)
Aug-30-23 04:30PM	Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3) (Business Wire)
Aug-24-23 08:50AM	Alpine Immune Sciences, Inc. (ALPN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Aug-22-23 04:30PM	Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c) (Business Wire)
Aug-17-23 09:55AM	Does Alpine Immune Sciences, Inc. (ALPN) Have the Potential to Rally 25.38% as Wall Street Analysts Expect? (Zacks)
Aug-14-23 04:15PM	Alpine Immune Sciences Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-23-23 10:25AM	Alpine Immune Sciences, Inc. (NASDAQ:ALPN) surges 14%; private equity firms who own 38% shares profited along with institutions (Simply Wall St.)
Jun-22-23 07:43AM	Alpine Immune (ALPN) Stock Up 19% MTD, Will the Uptick Continue? (Zacks)
Jun-20-23 07:14PM	Alpine Immune Sciences, Inc. (ALPN) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks) +5.59%
May-19-23 04:30PM	Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses (Business Wire) +10.47%
May-11-23 04:15PM	Alpine Immune Sciences Reports First Quarter 2023 Financial Results (Business Wire)
May-05-23 07:04AM	Pinning Down Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) P/S Is Difficult Right Now (Simply Wall St.) +8.04%
May-01-23 04:30PM	Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference (Business Wire)
Mar-27-23 09:16AM	Even though Alpine Immune Sciences (NASDAQ:ALPN) has lost US$39m market cap in last 7 days, shareholders are still up 200% over 3 years (Simply Wall St.) -6.04%
07:08AM	Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 10:02AM	Q4 2022 Alpine Immune Sciences Inc Earnings Call (Thomson Reuters StreetEvents) -8.25%
Mar-23-23 05:35PM	Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Mar-20-23 04:30PM	Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences (Business Wire) -5.01%
Mar-16-23 05:30PM	Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting (Business Wire)
Mar-15-23 04:30PM	Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-28-23 04:33PM	Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences (Business Wire)
Feb-13-23 05:16AM	Alpine Immune Sciences, Inc. (NASDAQ:ALPN) most popular amongst private equity firms who own 38% of the shares, institutions hold 33% (Simply Wall St.)
Feb-09-23 04:45PM	Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference (Business Wire)
Jan-17-23 08:36AM	Are Options Traders Betting on a Big Move in Alpine (ALPN) Stock? (Zacks)

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which focusses on discovering and developing innovative, protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rickey James Paul	See Remarks	Jan 26 '24	Option Exercise	8.30	117,764	977,844	73,764	Jan 29 07:04 PM
Rickey James Paul	See Remarks	Jan 26 '24	Sale	23.32	117,764	2,745,830	0	Jan 29 07:04 PM
Rickey James Paul	See Remarks	Jan 25 '24	Option Exercise	6.51	236	1,536	236	Jan 29 07:04 PM
Rickey James Paul	See Remarks	Jan 25 '24	Sale	22.00	236	5,192	0	Jan 29 07:04 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 28 '23	Option Exercise	12.74	74,441	948,378	2,675,421	Dec 29 07:32 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 28 '23	Option Exercise	0.65	1,016	660	1,016	Dec 29 07:32 PM
ORBIMED ADVISORS LLC	Director	Dec 28 '23	Sale	18.35	1,364,849	25,049,034	264,315	Dec 29 04:18 PM
Thompson Peter A.	Director	Dec 28 '23	Sale	18.35	1,364,849	25,049,034	264,315	Dec 29 04:20 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 28 '23	Sale	20.04	1,016	20,362	0	Dec 29 07:32 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 27 '23	Option Exercise	0.65	29,573	19,222	29,573	Dec 27 09:07 PM
ORBIMED ADVISORS LLC	Director	Dec 27 '23	Sale	19.96	181,498	3,622,700	406,609	Dec 29 04:18 PM
Thompson Peter A.	Director	Dec 27 '23	Sale	19.96	181,498	3,622,700	406,609	Dec 29 04:20 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 27 '23	Sale	20.04	29,573	592,717	0	Dec 27 09:07 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 26 '23	Option Exercise	0.63	24,486	15,436	24,486	Dec 27 09:07 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 26 '23	Sale	20.22	24,486	495,217	0	Dec 27 09:07 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 22 '23	Option Exercise	0.45	37,825	17,021	37,825	Dec 27 09:07 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 22 '23	Sale	20.43	37,825	772,595	0	Dec 27 09:07 PM
Rickey James Paul	See Remarks	Dec 19 '23	Option Exercise	5.02	15,213	76,369	15,213	Dec 21 07:35 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 19 '23	Option Exercise	0.45	2,402	1,081	2,402	Dec 21 07:34 PM
Rickey James Paul	See Remarks	Dec 19 '23	Sale	19.21	15,213	292,222	0	Dec 21 07:35 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 19 '23	Sale	20.01	2,402	48,064	0	Dec 21 07:34 PM
Rickey James Paul	See Remarks	Dec 18 '23	Option Exercise	5.02	1,800	9,036	1,800	Dec 18 09:20 PM
Rickey James Paul	See Remarks	Dec 18 '23	Sale	19.00	1,800	34,203	0	Dec 18 09:20 PM
Rickey James Paul	See Remarks	Dec 15 '23	Option Exercise	5.02	45,387	227,843	45,387	Dec 18 09:20 PM
Rickey James Paul	See Remarks	Dec 15 '23	Sale	19.09	45,387	866,383	0	Dec 18 09:20 PM
Rickey James Paul	See Remarks	Dec 14 '23	Option Exercise	5.02	11,600	58,232	11,600	Dec 18 09:20 PM
Rickey James Paul	See Remarks	Dec 14 '23	Sale	19.00	11,600	220,406	0	Dec 18 09:20 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 12 '23	Option Exercise	0.45	8,613	3,876	8,613	Dec 12 09:02 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 12 '23	Sale	17.32	41,063	711,026	0	Dec 12 09:02 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 11 '23	Sale	17.26	68,870	1,189,027	32,450	Dec 12 09:02 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 08 '23	Sale	17.08	8,067	137,784	101,320	Dec 12 09:02 PM
Rickey James Paul	See Remarks	Dec 06 '23	Option Exercise	3.23	6,446	20,821	6,446	Dec 06 07:31 PM
Rickey James Paul	See Remarks	Dec 06 '23	Sale	16.08	6,446	103,650	0	Dec 06 07:31 PM
Rickey James Paul	See Remarks	Dec 05 '23	Option Exercise	3.23	418	1,350	418	Dec 06 07:31 PM
Rickey James Paul	See Remarks	Dec 05 '23	Sale	16.01	418	6,694	0	Dec 06 07:31 PM
Rickey James Paul	See Remarks	Dec 04 '23	Option Exercise	3.23	63,947	206,549	63,947	Dec 06 07:31 PM
Rickey James Paul	See Remarks	Dec 04 '23	Sale	16.06	63,947	1,026,887	0	Dec 06 07:31 PM
Rickey James Paul	See Remarks	Nov 30 '23	Option Exercise	3.23	700	2,261	700	Dec 01 05:00 PM
Rickey James Paul	See Remarks	Nov 30 '23	Sale	16.00	700	11,200	0	Dec 01 05:00 PM
Rickey James Paul	See Remarks	Nov 06 '23	Option Exercise	3.23	10,989	35,494	18,003	Nov 08 05:20 PM
Rickey James Paul	See Remarks	Nov 06 '23	Sale	16.03	18,003	288,554	0	Nov 08 05:20 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ABIO

ARCA biopharma Inc

ALPN

Alpine Immune Sciences Inc

Upgrade your FINVIZ experience